CareDx, Inc
CDNA
Rang in Aktien
#4468
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Aktienkurs
$66.37
Marktkapitalisierung
$3.43B
Veränderung (1 Tag)
3.70%
Veränderung (1 Jahr)
360.57%
Land
US
Handel CareDx, Inc (CDNA)
Kategorie
Healthcare
Gewinn für CareDx, Inc (CDNA)
Gewinn im Jun 2026 TTM: $115.19M
Laut den aktuellen Finanzberichten von CareDx, Inc betragen die aktuellen Gewinne des Unternehmens $115.19M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-190.14M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-76.23M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von CareDx, Inc von 2012 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $115.19M | 117.92% |
| 2024 | $52.86M | -127.80% |
| 2023 | $-190.14M | 149.42% |
| 2022 | $-76.23M | 137.58% |
| 2021 | $-32.09M | 62.47% |
| 2020 | $-19.75M | -17.53% |
| 2019 | $-23.95M | -50.33% |
| 2018 | $-48.22M | -15.81% |
| 2017 | $-57.27M | 38.46% |
| 2016 | $-41.36M | 201.76% |
| 2015 | $-13.71M | 1,806.40% |
| 2014 | $-719.00K | -79.70% |
| 2013 | $-3.54M | -29.99% |
| 2012 | $-5.06M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $7.61B | 6,505.49% |
US
|
|
| $4.76B | 4,033.97% |
US
|
|
| $-252.70M | -319.37% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 1,339.34% |
US
|
